Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Liquid Biopsy Shows Potential for Detecting Sarcomatoid Features in RCC

August 23rd 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Dr McGregor on Challenges and Future Research Directions in ccRCC

August 22nd 2024

Bradley McGregor, MD, discusses ongoing treatment challenges and future research directions in clear cell renal cell carcinoma.

From Bench to Bedside: HIF-2α Inhibition in RCC

August 22nd 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22nd 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Dr McGregor on the Future Implications of Ongoing Research in RCC

August 21st 2024

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Subsequent Therapy Shows No Difference in OS Following IO/TKI-Based Treatment in RCC

August 19th 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC

August 19th 2024

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC

August 16th 2024

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Dr Braun on the Current Kidney Cancer Treatment Paradigm

August 16th 2024

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC

August 15th 2024

Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.

Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCC

August 14th 2024

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment

August 9th 2024

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 9th 2024

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Dr Uzzo on a Biomarker Analysis of the IMmotion010 Trial in RCC

July 31st 2024

Robert Uzzo, MD, MBA, FACS, discusses a biomarker analysis of the IMmotion010 trial in patients with renal cell carcinoma.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Uzzo Elucidates the Potential Role of KIM-1 as a Biomarker in RCC

July 30th 2024

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.

Dr Dizman on the Impact of CBM588 on the Gut Microbiome in ICI-Treated Patients With RCC

July 29th 2024

Nazli Dizman, MD, discusses the impact of CBM588 on gut microbiome composition in patients with renal cell carcinoma who received immune checkpoint inhibitors in the first line.

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

July 23rd 2024

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.